Drug Profile
GPX 100
Latest Information Update: 21 Dec 2018
Price :
$50
*
At a glance
- Originator Gem Pharmaceuticals
- Class Anthracyclines; Cytostatic antibiotics
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Dec 2018 Akebia Therapeutics merged with Keryx Pharmaceuticals to form Akebia Therapeutics
- 03 Sep 2007 Discontinued - Phase-II for Cancer in USA (unspecified route)
- 12 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals